John Berriman
Direktor/Vorstandsmitglied bei AUTOLUS THERAPEUTICS PLC
Vermögen: 556 230 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Christian Itin | M | 59 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 17 Jahre |
| James F. Abell | M | - |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | 26 Jahre |
| Martin Murphy | M | 55 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 10 Jahre |
| Martin Pulé | M | 51 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 10 Jahre |
| Kapil Dhingra | M | 64 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 14 Jahre |
| Malcolm Weir | M | 65 |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 17 Jahre |
| Cynthia Butitta | F | 70 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 6 Jahre |
| Gordon Hamilton | M | - |
Depixus SAS
 Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Joseph Anderson | M | 65 |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 20 Jahre |
| Charles H. Large | M | - |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | 13 Jahre |
| Linda Bain | F | 53 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 6 Jahre |
| Giuseppe S. Alvaro | M | - |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | 13 Jahre |
| Olivia Manser | F | - | 2 Jahre | |
| Kevin Fitzgerald | M | 56 | 19 Jahre | |
| Alex Driggs | M | 48 | - | |
| David Brochu | M | - | 5 Jahre | |
| Steve Allen | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Dieter Weinand | M | 63 |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | 1 Jahre |
| Alexander Swan | M | - | 3 Jahre | |
| Robert Scott | M | 70 |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | 4 Jahre |
| Atul Pande | M | 69 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| Michael Owen | M | 73 | 9 Jahre | |
| Robert Dolski | M | 54 | 1 Jahre | |
| Veronica Hersberger | M | - | 1 Jahre | |
| Julia Wilson | F | - | - | |
| Barbara Domayne Hayman | M | - |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| Brent Rice | M | 58 | 3 Jahre | |
| Ronald M. Lindsay | M | 76 |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Thibault Roulon | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Elaine Jones | M | 69 |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| Barbara Domayne-Hayman | M | - |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| Suzanne Hancock | F | - | 7 Jahre | |
| Kate Bingham | F | 58 |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| Christopher Vann | M | 59 | 8 Jahre | |
| Mark Chin | M | 42 |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Genghis Lloyd-Harris | M | 67 |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | 20 Jahre |
| Elisabeth Leiderman | M | 47 | 1 Jahre | |
| Lachlan Mackinnon | M | - |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | - |
| Miles Congreve | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 16 Jahre |
| Robert Azelby | M | 56 | - | |
| Shaun Stapleton | M | - | 9 Jahre | |
| Robert Iannone | M | 57 | 1 Jahre | |
| Bobby G. Soni | M | 53 |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | - |
| William Young | M | 79 | 3 Jahre | |
| Miranda Neville | F | - | 6 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Matthias Alder | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 11 Jahre |
| John Hawkins | M | 58 | 10 Jahre | |
| Lucinda Crabtree | M | 45 | 3 Jahre | |
| Edwin Moses | M | 69 | 14 Jahre | |
| Timothy Corn | M | 73 | 10 Jahre | |
| Mike Mason | M | 49 | 14 Jahre | |
| Fiona Hamilton Marshall | M | 59 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
| Jay Backstrom | M | 69 | 3 Jahre | |
| Per Anders Göte Samuelsson | M | 63 | - | |
| Ingrid Beichmann Wiik | F | 79 | - | |
| Achim Plum | M | 55 | 9 Jahre | |
| Claudia D'Augusta | M | 54 | 3 Jahre | |
| Roy Hartvig Larsen | M | 62 | 9 Jahre | |
| Richard Henderson | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
| Aron Braun | M | - | 7 Jahre | |
| Eva-Lotta Allan | F | 65 | 7 Jahre | |
| Hilde Hermansen Steineger | M | 58 | - | |
| Dinah Sah | M | 63 | 7 Jahre | |
| Olav Hellebø | M | 59 | 8 Jahre | |
| Günther Reiter | M | 70 | 16 Jahre | |
| Albert Weber | M | 60 | 21 Jahre | |
| Peter Johann | M | 67 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
| Mats Gunnar Pettersson | M | 78 | 6 Jahre | |
| Remi Vermeiren | M | 84 | - | |
| Joseph Slattery | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 5 Jahre |
| Geert Cauwenbergh | M | 70 | 6 Jahre | |
| Barry Greene | M | 60 | 17 Jahre | |
| Trevor Jones | M | 82 | 13 Jahre | |
| John Johnson | M | 66 | 3 Jahre | |
| Kevin Starr | M | 61 | 15 Jahre | |
| Ann Kessler | M | 81 | - | |
| Christopher Evans | M | 67 | - | |
| Michael Steinmetz | M | 75 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
| Wim Ottevaere | M | 68 | 12 Jahre | |
| Simon Cartmell | M | 64 | 9 Jahre | |
| Patricia Allen | F | 62 | 7 Jahre | |
| Bryan Geoffrey Morton | M | 67 | 7 Jahre | |
| Mark James Docherty | M | 60 | 12 Jahre | |
| Peter John Fellner | M | 80 |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | 14 Jahre |
| Kari Grønås Dyvik | F | 60 | - | |
| Nushmia Khokhar | M | - | - | |
| Roger Charles Harrison | M | 70 | - | |
| Mark Evans | M | 60 | 2 Jahre | |
| Julian Howell | M | - | - | |
| Roderick Verhelst | M | - |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | 1 Jahre |
| Lubomir Nechev | M | - | - | |
| Vicki Sato | M | 75 | 6 Jahre | |
| Robert A. Millman | M | - | - | |
| Andrew Sledziewski | M | - | - | |
| Cynthia Clayton | F | - | - | |
| Thomas R. Ulich | M | 70 | 1 Jahre | |
| Gerrit Franciscus Landolt | M | 60 | 14 Jahre | |
| Paul Harper | M | 77 | 12 Jahre | |
| James L. Vincent | M | 84 | 5 Jahre | |
| Vincent J. Miles | M | 73 | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 57 | 57,00% |
| Vereinigte Staaten | 18 | 18,00% |
| Belgien | 10 | 10,00% |
| Norwegen | 6 | 6,00% |
| Frankreich | 6 | 6,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Berriman
- Persönliches Netzwerk
